Vice President Kamala Harris on the campaign trail has frequently touted capping the price of insulin at $35 a month as a ...

Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation ...

Eli Lilly’s blockbuster weight loss and diabetes drugs missed analysts’ expectations by 18% in the third quarter, which were ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

Sales of Lilly's diabetes treatment Mounjaro and weight ... He noted that Lilly “is just getting started in commercializing obesity products globally.” Lilly CEO David Ricks told analysts ...

Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to ...

Lilly had a commercially available insulin for humans made with recombinant DNA. 5 The 1980s were a particularly strong time for diabetes awareness and research, in part due to insulin made of ...

Positive Phase 3 data included the 176-week study of tirzepatide showing 94% reduction in the risk of developing type 2 diabetes in adults ... 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE ...

Sanofi and Eli Lilly - implemented price cuts of up to 78% for some of their insulin products and expanded discounts offered by patient assistance programs. None of these measures is protected by ...